Resistin is associated with overall survival in non-small cell lung cancer patients during nivolumab treatment.
Aldo BonaventuraFrancesco GrossiFederico CarboneAlessandra VecchièS MinettiN BardiE EliaA M AnsaldoD FerraraE RijavecM G Dal BelloGiovanni RossiF BielloM TagliamentoAngela AlamaSimona CocoP SpallarossaFranco DallegriCarlo GenovaFabrizio MontecuccoPublished in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2020)
Resistin levels > 19 ng/mL at the time of the second cycle of nivolumab treatment independently predict a reduced OS in patients with advanced NSCLC.